Harbor Capital Advisors Inc. Sells 2,429 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Harbor Capital Advisors Inc. decreased its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 2.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 84,873 shares of the biotechnology company’s stock after selling 2,429 shares during the period. Harbor Capital Advisors Inc.’s holdings in Ascendis Pharma A/S were worth $11,684,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Groupama Asset Managment acquired a new stake in Ascendis Pharma A/S during the third quarter worth approximately $60,000. Janus Henderson Group PLC grew its holdings in shares of Ascendis Pharma A/S by 6.8% during the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock worth $625,075,000 after purchasing an additional 267,881 shares in the last quarter. Avoro Capital Advisors LLC increased its position in shares of Ascendis Pharma A/S by 5.8% in the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after purchasing an additional 229,995 shares during the period. Westfield Capital Management Co. LP raised its stake in Ascendis Pharma A/S by 3.4% in the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock valued at $766,523,000 after purchasing an additional 170,942 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in Ascendis Pharma A/S by 9.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock worth $278,760,000 after purchasing an additional 155,971 shares during the period.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND traded down $4.83 during midday trading on Friday, hitting $129.60. 120,316 shares of the company traded hands, compared to its average volume of 352,899. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $161.00. The firm has a market cap of $7.87 billion, a P/E ratio of -16.04 and a beta of 0.65. The stock has a 50-day moving average price of $132.53 and a 200 day moving average price of $133.60.

Analysts Set New Price Targets

ASND has been the topic of a number of recent analyst reports. Wells Fargo & Company lifted their price objective on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. TD Cowen dropped their price objective on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Oppenheimer lowered their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research note on Friday, November 15th. Citigroup raised their price target on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Finally, Wedbush reiterated an “outperform” rating and set a $181.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $192.07.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.